156 related articles for article (PubMed ID: 9593225)
1. Effects of F-1394, an acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on ACAT activity in HepG2 cells and on hepatic secretion of lipids in Triton WR-1339-induced hyperlipidemic rats: possible role of hepatic ACAT in very low density lipoprotein secretion.
Aragane K; Kusunoki J; Kitamine T; Yamaura T; Ohnishi H
Jpn J Pharmacol; 1998 Mar; 76(3):309-12. PubMed ID: 9593225
[TBL] [Abstract][Full Text] [Related]
2. Studies on acyl-CoA: cholesterol acyltransferase (ACAT) inhibitory effects and enzyme selectivity of F-1394, a pantotheic acid derivative.
Kusunoki J; Aragane K; Yamaura T; Ohnishi H
Jpn J Pharmacol; 1995 Mar; 67(3):195-203. PubMed ID: 7630037
[TBL] [Abstract][Full Text] [Related]
3. [Effect of F-1394, a potent and selective inhibitor of acyl-CoA:cholesterol acyltransferase (ACAT), on esterification of cholesterol and basolateral secretion of cholesteryl ester in Caco-2 cells].
Kusunoki J; Aragane K; Kitamine T; Yamaura T; Ohnishi H
Nihon Yakurigaku Zasshi; 1997 Dec; 110(6):357-65. PubMed ID: 9503394
[TBL] [Abstract][Full Text] [Related]
4. Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol.
Riddell D; Bright CP; Burton BJ; Bush RC; Harris NV; Hele D; Moore UM; Naik K; Parrott DP; Smith C; Williams RJ
Biochem Pharmacol; 1996 Oct; 52(8):1177-86. PubMed ID: 8937424
[TBL] [Abstract][Full Text] [Related]
5. Postprandial hyperlipidemia in streptozotocin-induced diabetic rats is due to abnormal increase in intestinal acyl coenzyme A:cholesterol acyltransferase activity.
Kusunoki J; Aragane K; Kitamine T; Kozono H; Kano K; Fujinami K; Kojima K; Chiwata T; Sekine Y
Arterioscler Thromb Vasc Biol; 2000 Jan; 20(1):171-8. PubMed ID: 10634814
[TBL] [Abstract][Full Text] [Related]
6. ACAT inhibitor F-1394 prevents intimal hyperplasia induced by balloon injury in rabbits.
Aragane K; Fujinami K; Kojima K; Kusunoki J
J Lipid Res; 2001 Apr; 42(4):480-8. PubMed ID: 11290819
[TBL] [Abstract][Full Text] [Related]
7. Hypocholesterolemic action and prevention of cholesterol absorption via the gut by F-1394, a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, in cholesterol diet-fed rats.
Kusunoki J; Aragane K; Kitamine T; Higashinakagawa S; Kase N; Yamaura T; Ohnishi H
Jpn J Pharmacol; 1995 Sep; 69(1):53-60. PubMed ID: 8847832
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of F 12511, (S)-2',3', 5'-trimethyl-4'-hydroxy-alpha-dodecylthioacetanilide a powerful and systemic acylcoenzyme A: cholesterol acyltransferase inhibitor.
Junquero D; Oms P; Carilla-Durand E; Autin J; Tarayre J; Degryse A; Patoiseau J; Colpaert FC; Delhon A
Biochem Pharmacol; 2001 Jan; 61(1):97-108. PubMed ID: 11137714
[TBL] [Abstract][Full Text] [Related]
9. Effect of F-1394, an acyl-CoA:cholesterol acyltransferase inhibitor, on atherosclerosis induced by high cholesterol diet in rabbits.
Aragane K; Kojima K; Fujinami K; Kamei J; Kusunoki J
Atherosclerosis; 2001 Sep; 158(1):139-45. PubMed ID: 11500184
[TBL] [Abstract][Full Text] [Related]
10. [Hypolipidemic action of F-1394, an acyl-CoA: cholesterol acyltransferase (ACAT) inhibitor, in high-fat diet fed beagle dogs].
Kusunoki J; Aragane K; Kitamine T; Yamaura T; Ohnishi H
Yakugaku Zasshi; 1997 Apr; 117(4):233-41. PubMed ID: 9167444
[TBL] [Abstract][Full Text] [Related]
11. Direct effect of an acyl-CoA:cholesterol acyltransferase inhibitor, F-1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice.
Chiwata T; Aragane K; Fujinami K; Kojima K; Ishibashi S; Yamada N; Kusunoki J
Br J Pharmacol; 2001 Aug; 133(7):1005-12. PubMed ID: 11487509
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol-lowering effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor, on cholesterol diet-fed rats and rabbits.
Azuma Y; Kawasaki T; Ikemoto K; Obata K; Ohno K; Sajiki N; Yamada T; Yamasaki M; Nobuhara Y
Jpn J Pharmacol; 1998 Nov; 78(3):355-64. PubMed ID: 9869270
[TBL] [Abstract][Full Text] [Related]
13. Relationship between bioavailability and hypocholesterolemic activity of YM17E, an inhibitor of ACAT, in cholesterol-fed rats.
Uchida T; Aoyama K; Watanabe T; Higuchi S
Atherosclerosis; 1998 Mar; 137(1):97-106. PubMed ID: 9568741
[TBL] [Abstract][Full Text] [Related]
14. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters.
Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K
Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459
[TBL] [Abstract][Full Text] [Related]
15. The hypolipidemic action of the ACAT inhibitor HL-004 in hamsters fed normal chow.
Murakami S; Ohta Y; Asami Y; Yamagishi I; Toda Y; Sato M; Tomisawa K
Gen Pharmacol; 1996 Dec; 27(8):1383-6. PubMed ID: 9304411
[TBL] [Abstract][Full Text] [Related]
16. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure.
Vaziri ND; Liang K
Am J Physiol Renal Physiol; 2004 Nov; 287(5):F1038-43. PubMed ID: 15280162
[TBL] [Abstract][Full Text] [Related]
17. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice.
Kusunoki J; Hansoty DK; Aragane K; Fallon JT; Badimon JJ; Fisher EA
Circulation; 2001 May; 103(21):2604-9. PubMed ID: 11382731
[TBL] [Abstract][Full Text] [Related]
18. Acyl-CoA:Cholesterol O-acyltransferase (ACAT) inhibitors. 2. 2-(1,3-Dioxan-2-yl)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT.
Astles PC; Ashton MJ; Bridge AW; Harris NV; Hart TW; Parrott DP; Porter B; Riddell D; Smith C; Williams RJ
J Med Chem; 1996 Mar; 39(7):1423-32. PubMed ID: 8691472
[TBL] [Abstract][Full Text] [Related]
19. Effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase inhibitor, on cholesterol esterification and high-density lipoprotein-induced cholesterol efflux in macrophages.
Azuma Y; Kawasaki T; Ikemoto K; Ohno K; Yamada T; Yamasaki M; Nobuhara Y
Jpn J Pharmacol; 1999 Feb; 79(2):159-67. PubMed ID: 10202851
[TBL] [Abstract][Full Text] [Related]
20. Effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase inhibitor, on cholesterol esterification and secretions of apolipoprotein B-containing lipoprotein and bile acids in HepG2.
Azuma Y; Kawasaki T; Ohno K; Seto J; Yamada T; Yamasaki M; Nobuhara Y
Jpn J Pharmacol; 1999 Feb; 79(2):151-8. PubMed ID: 10202850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
